Mangoceuticals, Inc., also known as MangoRx, announced on October 31, 2024, that it has regained compliance with Nasdaq's Minimum Bid Price Requirement. The company had previously been notified by Nasdaq on October 30, 2023, that its common stock did not meet the minimum bid price of $1.00 per share. MangoRx was initially given a 180-day grace period to comply, which was later extended by another 180 days to October 30, 2024. To address the issue, MangoRx implemented a 1-for-15 reverse stock split on October 16, 2024. This action proved successful as the company's stock price remained at or above $1.00 for 10 consecutive business days, leading to Nasdaq confirming the company's compliance and closing the matter. MangoRx, which specializes in men's health and wellness products through a telemedicine platform, also issued a press release regarding the regained compliance.

Mangoceuticals, Inc., also known as MangoRx, announced on October 31, 2024, that it has regained compliance with Nasdaq's Minimum Bid Price Requirement. The company had previously been notified by Nasdaq on October 30, 2023, that its common stock did not meet the minimum bid price of $1.00 per share. MangoRx was initially given a 180-day grace period to comply, which was later extended by another 180 days to October 30, 2024. To address the issue, MangoRx implemented a 1-for-15 reverse stock split on October 16, 2024. This action proved successful as the company's stock price remained at or above $1.00 for 10 consecutive business days, leading to Nasdaq confirming the company's compliance and closing the matter. MangoRx, which specializes in men's health and wellness products through a telemedicine platform, also issued a press release regarding the regained compliance.